Eplerenone
Links shared publicly online about this topic
Synthon announces European approvals for Eplerenone
news-medical.net — “Synthon has successfully concluded multiple registration procedures for the cardiovascular drug Eplerenone. Synthon has obtained regulatory clearance for the product in nine European countries, for both 25 and 50 mg film coated tablets.” View full resource at news-medical.net
Most Recently Shared on September 16, 2011 at 2:51 am By:
Synthon announces European approvals for Eplerenone: Synthon has successfully concluded multiple registration pr... http://t.co/Wra7N7SD
The Effect Of Eplerenone Vs. Placebo On Cardiovascular Mortality
medicalnewstoday.com — “Results from a new sub-analysis of the EMPHASIS-HF study showed significant reductions in death and hospitalization for five pre-defined high-risk patient sub-groups with chronic heart failure (CH” View full resource at medicalnewstoday.com
Most Recently Shared on August 30, 2011 at 1:20 pm By:
MedicalNewsToday: The Effect Of Eplerenone Vs. Placebo On Cardiovascular Mortality http://t.co/mUt5mgp Full http://t.co/12BmsBG
Eplerenone Reduces Risk of Cardiovascular Failure in Diabetics | diabetes
diabeticlive.com — “Eplerenone Reduces Risk of Cardiovascular Failure in Diabetics: The trial treated patients who had suffered NYHA class 2 systolic heart failure with eplerenone, an aldosterone blocker.” View full resource at diabeticlive.com
Most Recently Shared on August 31, 2011 at 1:11 pm By:
Eplerenone Reduces Risk of Cardiovascular Failure in Diabetics http://t.co/qiPh1gA
Symposier - Eplerenone Reduced Heart Failure Risks
symposier.com — “Uploaded and shared in Youtube by: ElsGlobalMedicalNews --" Eplerenone reduced the risk of death and hospitalization in patients with mild heart failure in the EMPHASIS trial, Dr. Faiez Zannad explains. See the related Internal Medicine News story at http://tinyurl.com/2c94f3w” View full resource at symposier.com
Most Recently Shared on November 15, 2010 at 6:11 pm By:
Symposier Cardiology Cardiology and Health Business
Eplerenone reduced the risk of death and hospitalization in patients with mild heart failure in the EMPHASIS trial. http://bit.ly/a4DEYA
The effect of eplerenone vs. placebo on cardiovascular mortality
medicalxpress.com — “Today results from a new sub-analysis of the EMPHASIS-HF study showed significant reductions in death and hospitalization for five pre-defined high-risk patient sub-groups with chronic heart failure (CHF) and mild symptoms treated with eplerenone in addition to standard therapy versus those treated ...” View full resource at medicalxpress.com
Most Recently Shared on August 29, 2011 at 2:15 pm By:
PhysOrg Health News Health News
The effect of eplerenone vs. placebo on cardiovascular mortality http://t.co/0zYZMMn
Eplerenone in mild HF trial stopped early due to drug benefit
theheart.org — “Pfizer is to halt recruitment of patients to the EMPHASIS-HF trial testing its selective aldosterone inhibitor eplerenone in mild heart-failure patients because of a significant benefit of the drug.” View full resource at theheart.org
Most Recently Shared on May 28, 2010 at 3:42 pm By:
Pfizer halts eplerenone HF trial early due to drug benefit: Pfizer is to halt recruitment of patients to the EMPHA... http://bit.ly/adkX5w
Eplerenone: An Underused Medication http://is.gd/i9PMV
blog.mdlinx.com — “Eplerenone: An Underused Medication http://is.gd/i9PMV” View full resource at blog.mdlinx.com
Most Recently Shared on December 3, 2010 at 8:50 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Eplerenone: An Underused Medication http://is.gd/i9PMV
EPLERENONE FOR GITELMAN SYNDROME IN PREGNANCY - Morton - 2011 - Nephrology - Wiley Online Library
onlinelibrary.wiley.com — “EPLERENONE FOR GITELMAN SYNDROME IN PREGNANCY - Morton - 2011 - Nephrology - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on February 24, 2011 at 2:16 am By:
Urology & Nephrology OW Health
Eplerenone for gitelman syndrome in pregnancy: (Source: Nephrology) http://bit.ly/fpsGg8
New Results from EMPHASIS-HF Show Big Benefits For High Risk Subgroups Taking Eplerenone - Forbes
forbes.com — “Last November the main results of the EMPHASIS-HF trial demonstrated that eplerenone was significantly better than placebo in reducing the risk of death and hospitalization in patients with systolic heart failure and mild symptoms. Now a new analysis of the trial, presented by Bertram Pitt at the European Society of [...]” View full resource at forbes.com
Most Recently Shared on August 29, 2011 at 6:16 pm By:
Drugs and Devices OW OW Health
New Results from EMPHASIS-HF Show Big Benefits For High Risk Subgroups Taking Eplerenone: Last November... http://t.co/M5fy6Ho #drug
EMPHASIS-HF: Eplerenone reduced death, hospitalization by 37% in systolic heart failure
endocrinetoday.com — “American Heart Association Scientific Sessions 2010 CHICAGO — Eplerenone was associated with a 37% reduction in the risk of death or ho” View full resource at endocrinetoday.com
Most Recently Shared on November 15, 2010 at 5:15 pm By:
EMPHASIS-HF: Eplerenone reduced death, hospitalization by 37% in systolic heart failure http://ow.ly/3a175 #AHA2010
Eplerenone trial stopped early after reaching its primary endpoint, Pfizer announces « CardioBrief
cardiobrief.org — “Eplerenone trial stopped early after reaching its primary endpoint, Pfizer announces « CardioBrief” View full resource at cardiobrief.org
Most Recently Shared on May 27, 2010 at 12:52 pm By:
Stephen L. Sigal, MD, MS, FACC, FAHA Doctor, Internist, Cardiologist, and Physician
Pfizer stops EMPHASIS-HF trial early: Eplerenone decreased CV death and heart failure admissions in pts with mild HF http://bit.ly/dqc1EZ
AHA: Eplerenone Reduced Mortality 24% in Mild Heart Failure : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on November 15, 2010 at 8:04 pm By:
Bob Finn - Medical News Net Health News
Eplerenone reduces mortality in mild heart failure by 24% in large study, @pwendl reports. http://bit.ly/dCVsKC
Eplerenone Effective Across All High-Risk Heart Failure Patients : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on August 29, 2011 at 7:18 pm By:
Bob Finn - Medical News Net Health News
Eplerenone cut cardiovascular events significantly across all risk levels in patients with mild heart failure http://t.co/ElOI6Wp
Adding Inspra(R) (Eplerenone) To Standard Therapy Reduces The Incidence Of New Onset AF/F In Patients With Systolic Heart Failure, Sub-Analysis Shows
medicalnewstoday.com — “Pfizer Inc. (NYSE: PFE) today announced results from a pre-specified sub-analysis1 of the EMPHASIS-HF trial2 which showed that Inspra® (eplerenone), added to standard recommended therapy, stat” View full resource at medicalnewstoday.com
Most Recently Shared on May 23, 2011 at 12:05 pm By:
MNT Cardiovascular Health News
Adding Inspra(R) (Eplerenone) To Standard Therapy Reduces The Incidence Of New Onset AF/F In Patients With Systolic He... http://mnt.to/3WcC
ESC | Congresses | ESC Congress 2011 | EMPHASIS-HF - The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure: An analysis of the High-risk groups in
escardio.org — “Congress report, ESC congress 2011,Hot Line II - Frontiers in interventional and device treatments,Infarction acute phase non STEMI” View full resource at escardio.org
Most Recently Shared on August 29, 2011 at 10:55 am By:
European Cardiology Cardiology and Medical Society
EMPHASIS-HF hot line report http://ow.ly/6ffSc #escparis2011
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
News-Medical.Net
Medical News from Around the World
-
Heart Health
Get the latest news, information, and research on your heart. Re-tweet if you want.
-
diabeticlive
diabetic live provides fresh content every Monday, Wednesday and Friday and provides inspiring stories of those living with diabetes.
Advertisement
